AspRS Polypeptide Fragments Modulate Non-Canonical Biological Activities
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current understanding of aminoacyl-tRNA synthetases primarily focuses on their canonical functions in translation, with limited exploration of their non-canonical biological activities, which could have therapeutic potential.
Innovation Solution
Identification and characterization of aspartyl-tRNA synthetase (AspRS) polypeptides with non-canonical activities, including modulation of cell proliferation, apoptosis, inflammation, angiogenesis, and cytokine production, through specific fragments, variants, and fusion proteins, along with associated methods for their application in therapeutic contexts.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Loss of information
If aminoacyl-tRNA synthetases are studied primarily for their canonical translation functions, then the understanding of protein synthesis is improved, but the exploration of their non-canonical biological activities is limited
Solution Approach 1:
The patent identifies that aminoacyl-tRNA synthetases possess multiple functions beyond their canonical role in translation. Specifically, AspRS and its fragments are shown to have non-canonical activities including modulation of cell proliferation, apoptosis, inflammation, angiogenesis, and cytokine production. This multi-functionality principle resolves the contradiction by expanding the known functional repertoire of these enzymes, thereby recovering lost information about their biological activities while enhancing their therapeutic versatility.
2Reliability
If full-length AspRS is used, then canonical aminoacylation activity is maintained, but non-canonical biological activities may be masked or reduced
Solution Approach 1:
The patent applies segmentation by dividing the full-length AspRS into multiple fragments of varying lengths (e.g., residues 1-200, 1-400, or specific domains). These fragments are designed to retain non-canonical biological activities such as anti-inflammatory and anti-angiogenic effects while minimizing canonical aminoacylation activity. This segmentation resolves the contradiction by separating the different functional activities spatially within the protein structure, allowing selective exploitation of non-canonical functions for therapeutic purposes.
Solution Approach 2:
The patent extracts specific functional domains or fragments from the full-length AspRS that are responsible for non-canonical activities. By isolating these specific regions (such as N-terminal fragments or specific domains), the invention recovers and enhances the therapeutic activities that were previously masked or diluted in the full-length protein, while the extracted fragments can be used independently for therapeutic applications.
3Adaptability or versatility
If truncated forms of AspRS are generated to enhance non-canonical activities, then therapeutic potential is improved, but structural complexity and production challenges increase
Solution Approach 1:
The patent systematically varies parameters such as fragment length, amino acid sequence composition, and domain inclusion to optimize the balance between therapeutic activity and manufacturability. Different fragment configurations (e.g., varying N-terminal truncations, specific domain combinations) are evaluated to identify optimal versions that maintain high non-canonical activity while being amenable to standard protein production methods. This parameter optimization resolves the contradiction by finding the sweet spot between enhanced therapeutic versatility and practical ease of manufacture.
Data Source
AI summary
Isolated aspartyl-tRNA synthetase polypeptides and polynucleotides having non-canonical biological activities are provided, as well as compositions and methods related thereto.